ABG
OVID icon

Ally Bridge Group’s Ovid Therapeutics OVID Stock Holding History

Ally Bridge Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.26M Buy
2,818,459
+1,033,459
+58% +$1.85M 5.05% 5
2025
Q4 		$2.91M Buy
+1,785,000
New +$2.75M 3.03% 13

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ally Bridge Group's OVID Position: Q1 2026 in Review

Ally Bridge Group increased its Ovid Therapeutics (OVID) stake by 58% in Q1 2026, buying an estimated $1.85M and bringing the position to 2,818,459 shares worth $6.26M. The position accounts for 5.05% of the portfolio, ranked #5.

Ally Bridge Group first reported a position in OVID in Q4 2025 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Ally Bridge Group held 2,818,459 shares of Ovid Therapeutics worth $6.26M as of Q1 2026.
  • Ally Bridge Group bought 1,033,459 Ovid Therapeutics shares in Q1 2026, an estimated $1.85M.
  • Ovid Therapeutics made up 5.05% of Ally Bridge Group's portfolio in Q1 2026, its #5 holding.
  • Ally Bridge Group first reported a position in Ovid Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Ally Bridge Group's 13F filing for Q1 2026, filed 18 May 2026.